Gallbladder cancer is diagnosed through a combination of imaging scans, blood tests, and sometimes tissue biopsies, though a surprising number of cases are found by accident. Roughly 0.14% to 1.07% of people who have their gallbladder removed for what’s assumed to be a benign condition like gallstones turn out to have cancer when the tissue is examined afterward. For those who aren’t diagnosed incidentally, the path to diagnosis typically starts with symptoms that prompt imaging and lab work.
Symptoms That Trigger Investigation
Gallbladder cancer rarely causes obvious symptoms in its early stages, which is one reason it’s often caught late. When symptoms do appear, abdominal pain in the upper right side is the most common. Jaundice, a yellowing of the skin, gums, and whites of the eyes, develops when a tumor grows large enough to block the bile ducts, trapping a yellow-green substance called bilirubin in the blood.
Nausea, vomiting, and lumps in the abdomen that a doctor can feel during a physical exam are other signs that may prompt further testing. Less common symptoms include unexplained weight loss, loss of appetite, itchy skin, dark urine, and pale or greasy stools. None of these symptoms are unique to gallbladder cancer, which is part of what makes diagnosis difficult. They overlap heavily with gallstones, bile duct problems, and other liver conditions.
Blood Tests and Liver Function
Blood work is usually one of the first steps. Liver function tests measure several enzymes and substances that rise when bile flow is blocked or the liver is under stress. The key markers include alkaline phosphatase (ALP), which climbs when bile ducts are obstructed, and bilirubin, the pigment that causes jaundice. Normally, bilirubin levels fall between 0.1 and 1.2 milligrams per deciliter, and ALP ranges from 40 to 129 units per liter. Elevated numbers don’t confirm cancer on their own, but they signal that something is blocking bile drainage and warrant imaging.
Doctors may also check tumor markers in the blood. CA 19-9 is the more useful of the two markers commonly tested. At a cutoff of 20 units per milliliter, it correctly identifies about 79% of gallbladder cancer cases, with a specificity around 79%. CEA, the other marker, is less reliable, catching only about 50% of cases. Neither marker is accurate enough to diagnose cancer alone. They’re most helpful when combined with imaging results or used to monitor treatment response later on.
Imaging: The Core of Diagnosis
Ultrasound is typically the first imaging test ordered because it’s quick, radiation-free, and good at distinguishing between a cancerous mass and benign gallstone disease. It can show the tumor’s location, size, and whether major blood vessels are involved.
CT scans provide more detailed, cross-sectional images of the gallbladder, liver, bile ducts, and nearby lymph nodes. Some centers use triphasic CT scans, which capture images during three different phases of blood flow through the liver. This helps doctors see not just the primary tumor but whether cancer cells have spread to surrounding structures.
MRI and a specialized version called magnetic resonance cholangiopancreatography (MRCP) add another layer of detail. Standard MRI helps determine whether a tumor has reached the liver or other organs. MRCP focuses specifically on the bile ducts and pancreatic ducts, making it particularly useful for spotting blockages, narrowing, or dilation in the biliary system. MRCP is noninvasive and doesn’t require sedation, unlike its more invasive counterpart, ERCP.
PET scans detect whether cancer has traveled beyond the gallbladder to distant tissues or organs. They’re sometimes combined with CT (PET-CT) to pinpoint the exact location of tumors throughout the body. This combination is especially valuable for staging, helping doctors understand how far the disease has progressed before planning treatment.
ERCP: Diagnosis and Treatment in One Procedure
Endoscopic retrograde cholangiopancreatography (ERCP) looks for the same bile duct and pancreatic problems as MRCP, but it’s an invasive procedure that requires anesthesia. A thin, flexible tube is passed through the mouth and into the small intestine to access the bile ducts directly. The advantage of ERCP is that it’s not just diagnostic. During the same procedure, doctors can place stents to open blocked ducts, remove stones, and collect tissue samples for biopsy. If imaging has already identified a blockage causing jaundice, ERCP can relieve that blockage while simultaneously gathering information about the tumor.
Biopsy and Tissue Sampling
A definitive cancer diagnosis requires examining tissue under a microscope. How that tissue is obtained depends on the situation. In many cases, no pre-surgical biopsy is performed at all. If imaging strongly suggests cancer, surgeons may proceed directly to removing the gallbladder and send the tissue to pathology afterward.
When a biopsy is needed before surgery, endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is one option. This involves guiding a needle through the digestive tract wall and into the mass using ultrasound imaging. However, this approach carries risks specific to the gallbladder, including bile leakage and the possibility of needle track seeding, where cancer cells spread along the path of the needle. To minimize this risk, doctors take precautions like avoiding puncturing through fluid-filled spaces. If the cancer has already spread to the liver or lymph nodes, those metastases are typically biopsied first, since sampling them is safer than puncturing the gallbladder mass directly. EUS-FNA of the gallbladder itself is generally reserved for larger masses that extend into the bile duct or liver, where the needle can reach tumor tissue without passing through the gallbladder cavity.
Incidental Discovery During Surgery
A significant portion of gallbladder cancers are found unexpectedly. When someone has a cholecystectomy (gallbladder removal) for gallstones or chronic inflammation, the removed tissue is routinely sent to a pathology lab. Studies from multiple countries put the rate of incidental gallbladder cancer at roughly 0.14% to 1.07% of all cholecystectomies performed for presumed benign disease, with most estimates clustering below 1%. While those percentages sound small, the sheer volume of gallbladder removals performed worldwide means this pathway accounts for a meaningful share of all gallbladder cancer diagnoses. Cancers caught this way tend to be at an earlier stage, which generally means better treatment options.
Distinguishing Cancer From Benign Conditions
One of the trickiest parts of diagnosing gallbladder cancer is separating it from inflammatory conditions that can look similar on imaging. Xanthogranulomatous cholecystitis (XGC), a rare form of gallbladder inflammation, is a particularly common mimic. On imaging, gallbladder cancer tends to show limited wall thickening with disrupted inner lining integrity, while XGC often features distinctive low-density nodules in the gallbladder wall that can help distinguish it from cancer.
Combining CT and MRI findings improves accuracy significantly. One diagnostic model using 11 imaging features, including characteristics of wall nodules, the presence of gallstones, bile duct dilation, and fat signals within the wall, achieved about 90% accuracy in distinguishing XGC from cancer. A standardized reporting system called GB-RADS has also been developed to help radiologists use consistent language when describing gallbladder features on ultrasound, reducing ambiguity in reports.
How Staging Works
Once gallbladder cancer is confirmed, it’s staged using the TNM system from the American Joint Committee on Cancer. This system evaluates three things: how deeply the tumor has grown into the gallbladder wall (T), whether it has reached nearby lymph nodes (N), and whether it has spread to distant organs (M).
Early-stage tumors (Stage I) are confined to the inner layers of the gallbladder wall. Stage II cancers have grown into the connective tissue beyond the muscle layer but haven’t reached the liver or other organs. Stage III means the tumor has either broken through the gallbladder’s outer lining, invaded the liver or a neighboring organ, or spread to one to three nearby lymph nodes. Stage IV is the most advanced: the tumor involves major blood vessels like the portal vein or hepatic artery, has reached four or more lymph nodes, or has spread to distant sites in the body.
The distinction between Stage IIA and IIB matters for surgical planning. Stage IIA tumors grow toward the abdominal cavity side of the gallbladder, while Stage IIB tumors grow toward the liver side. This difference in direction affects how aggressively surgeons need to operate and what structures may need to be removed along with the gallbladder.